Novel dihydropyrazine analogues as NPY antagonists.

Bioorg Med Chem Lett

Department of Neuroscience/Genitourinary Drug Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492-7660, USA.

Published: February 2002

The dihydropyridine is currently one of the lead compounds in the neuropeptide-Y(1) (NPY-Y(1)) receptor antagonist program. Compound is a selective, high affinity ligand at the NPY-Y(1) receptors (IC(50)=4.2 nM) in SK-N-MC cells. To further expand the SAR study surrounding this dihydropyridine core structure we succeeded in synthesizing an analogous series of dihydropyrazine derivatives. This structural modification yielded compounds substantially different from the parent molecules in terms of molecular polarization and electron distribution while the overall molecular structure was generally preserved. This altered property should therefore provide us with additional SAR information on the optimal binding requirement with NPY receptors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(01)00765-xDOI Listing

Publication Analysis

Top Keywords

novel dihydropyrazine
4
dihydropyrazine analogues
4
analogues npy
4
npy antagonists
4
antagonists dihydropyridine
4
dihydropyridine currently
4
currently lead
4
lead compounds
4
compounds neuropeptide-y1
4
neuropeptide-y1 npy-y1
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!